ACB
CHRS icon

Aristotle Capital Boston’s Coherus Oncology CHRS Stock Holding History

Aristotle Capital Boston’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,342,977
Closed -$8.76M – 132
2023
Q3 		$8.76M Buy
2,342,977
+36,936
+2% +$171K 0.28% 113
2023
Q2 		$9.85M Buy
2,306,041
+51,939
+2% +$306K 0.3% 108
2023
Q1 		$15.4M Buy
2,254,102
+167,528
+8% +$1.3M 0.48% 81
2022
Q4 		$16.5M Sell
2,086,574
-54,806
-3% -$422K 0.52% 79
2022
Q3 		$20.6M Sell
2,141,380
-180,788
-8% -$1.83M 0.7% 59
2022
Q2 		$16.8M Buy
2,322,168
+129,566
+6% +$1.13M 0.5% 91
2022
Q1 		$28.3M Buy
2,192,602
+105,415
+5% +$1.34M 0.71% 64
2021
Q4 		$33.3M Sell
2,087,187
-68,034
-3% -$1.19M 0.78% 52
2021
Q3 		$34.6M Buy
2,155,221
+164,778
+8% +$2.42M 0.81% 50
2021
Q2 		$27.5M Sell
1,990,443
-111,244
-5% -$1.58M 0.63% 72
2021
Q1 		$30.7M Buy
2,101,687
+318,607
+18% +$5.41M 0.68% 64
2020
Q4 		$31M Buy
1,783,080
+845,806
+90% +$15.1M 0.73% 53
2020
Q3 		$17.2M Buy
937,274
+322,242
+52% +$5.99M 0.5% 82
2020
Q2 		$11M Buy
+615,032
New +$10.4M 0.33% 101

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristotle Capital Boston's CHRS Position: Q4 2023 in Review

Aristotle Capital Boston sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 2,342,977 shares — an estimated $8.76M sold.

Aristotle Capital Boston first reported a position in CHRS in Q2 2020 and held it in 14 quarters. The position peaked at $34.6M in Q3 2021. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Aristotle Capital Boston reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Aristotle Capital Boston sold 2,342,977 Coherus Oncology shares in Q4 2023, an estimated $8.76M.
  • Aristotle Capital Boston first reported a position in Coherus Oncology in Q2 2020 and held it in 14 quarters.
  • Aristotle Capital Boston's Coherus Oncology position peaked at $34.6M in Q3 2021.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Aristotle Capital Boston's 13F filing for Q4 2023, filed 14 Feb 2024.